Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital

Arab Journal of Gastroenterology

Volumn 14, Issue 3, 2013, Pages 123-125

  Dib, Jacobo ^a   Alvarez, Bethseidy ^a   Mendez, Liskie ^a   Cruz, Maria E ^a  

^a Hospital de Lidice Caracas   (Venezuela)

Author keywords

Helicobacter pylori; Levofloxacin

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VENEZUELA;

HELICOBACTER PYLORI; LEVOFLOXACIN;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; VENEZUELA; YOUNG ADULT;

EID: 84886288840     PISSN: 16871979     EISSN: 20902387     Source Type: Journal    
DOI: 10.1016/j.ajg.2013.09.001     Document Type: Article

References (26)

1. Urrestarazu M.I., Serrano N., Piñero R., Cavazza M.E. Susceptibilidad de Helicobacter pylori a los antimicrobianos. Rev Soc Ven Microbiol 2003, 3(1):20-22.
2. Perrone M., González-Valencia G., Camorlinga M., et al. Genotipos vacA de Helicobacter pylori en una población venezolana. Rev Soc Ven Microbiol 2009, 29(1):39-43.
3. Armanie E., Bohórquez J., Chiurillo M., et al. Hallazgos clínicos, edoscópicos e histológicos asociados a la infección por Helicobacter pylori considerando los genotipos cag a y vac a en pacientes con dispepsia. servicio de gastroenterología. hospital central universitario "Antonio María Pineda". Gen 2010, 64:76-80.
4. Gotoh A., KawaKami Y., Akahane T., et al. Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy. Microbiol Immunol 1997, 41:7-12.
5. Mégraud F., Doermann H.P. Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 1998, 43:S61-S65.
6. Al-Qurashi A.R., El-Morsy F., Al-Quorain A.A. Evolution of metronidazole and tetracycline susceptibility pattern in Helicobacter pylori at a hospital in Saudi Arabia. Int J Antimicrob Agents 2001, 17:233-236.
7. Ani A.E., Malu A.O., Onah J.A., et al. Antimicrobial susceptibility test of Helicobacter pylori isolated from Jos, Nigeria. Trans R Soc Trop Med Hyg 1999, 93:659-661.
8. Iovene M.R., Romano M., Pilloni A.P., et al. Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori. Chemotherapy 1999, 45:8-14.
9. Trespalacios A., Regino W., Reyes M. Resistencia de Helicobacter pylori a metronidazol, claritromicina y amoxicilina en pacientes colombianos. Rev Col Gastroenterol 2010, 25:1.
10. Xia H.X., Buckley M., Keane C.T., O'Morain C.A. Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother 1996, 37:473-481.
11. Mégraud F. Strategies to treat patients with antibiotic resistant Helicobacter pylori. Int J Antimicrob Agents 2000, 16:507-509.
12. Eisig J., Silva F., Barbuti R., et al. Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication. BMC Gastroenterol 2009, 9:38.
13. Wu Deng-Chyang, Hsu Ping-I, Tseng Hui-Hwa, et al. Helicobacter pylori infection a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine (Baltimore) 2011;90(3).
14. Molina-Infante J., Perez-Gallardo B., Fernandez-Bermejo M., et al. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010, 10:1077-1084.
15. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus report. Gut 2007, 56:772-781.
16. Antos D., Schneider-Brachert W., Bästlein E., et al. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006, 11(1):39-45.
17. Nista E.C., Candelli M., Cremonini F., et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003, 18(6):627-633.
18. Coelho L.G., Moretzsohn L.D., Vieira W.L., Gallo S., et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment Pharmacol Ther 2005, 21(6):783-787.
19. Gisbert Javier P. Second-line rescue therapy of Helicobacter Pylori infection. Therap Adv Gastroenterol 2009, 2(6):331-356.
20. Perri F., Festa V., Merla A., et al. Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther 2003, 18(8):815-820.
21. Wu D.C., Hsu P.I., Wu J.Y., et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010, 8:36-41.
22. Buzás G.M. First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010, 16(31):3865-3870.
23. Choi Kang Hyun, Chung Woo Chul, Lee Kang-Moon, et al. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011, 26(6):785-790.
24. Fock K.M., Katerlaris P., Sugano K., et al. Second Asia-Pacific Conference. Second Asia-Pacific Consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009, 24:1587-1600.
25. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010, 59:1143-1153.
26. De Francesco V., Giorgio F., Hassan C., Manes G., Vannella L., Panella C., et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010, 19(4):409-414.